Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Radiation therapy can treat lung cancer at all stages, easing symptoms, improving precision and minimizing side effects with ...

Thanks to federally funded cancer research and clinical trials at Johns Hopkins, John Ryan has been able to attend ...

Lung cancer is the leading cause of cancer death in Western Australia, and is also the most common and one of the least ...

Bayer announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's new drug application (NDA) and granted Priority Review designation for the investigational compound ...

AbbVie Inc. (NYSE:ABBV) has spotlighted major advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, ...

ASCO 2025 will showcase cutting-edge advancements in precision medicine, artificial intelligence, and biomarker-driven ...

Guardant Health, Inc. (NASDAQ:GH) has introduced major upgrades to its Guardant360 Liquid biopsy test, significantly ...

Findings seen for patients with extensive-stage small cell lung cancer, following standard induction therapy.

This priority review designation for sevabertinib in previously treated HER2-mutant non–small cell lung cancer is supported by data from the phase 1/2 SOHO-01 study.